Glaxo submits new drug application for asthma treatment

Stock Market News

Prices

Results Calendar charts

Charts

Watchlist

Share Tips news

News Home

30-06-2014 15:06

Add To Google +1

GlaxoSmithKline (GSK) on Monday announced that in partnership with US-listed Theravance it has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for two different doses of an asthma treatment taken through its Ellipta dry powder inhaler.

The filing of the nNDA is based on data from its clinical development programme for a certain type of long-acting inhaled corticosteroid drug used in the treatment of asthma in sufferers aged 12 and over.

The clinical development programme comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients with asthma.

Shares in GSK had fallen 0.7% to 1,562.50p by 14:10.

NR

Related share prices
GlaxoSmithKline (GSK) share price

Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.

Get a free widget for your website with our latest headlines.

You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.

Visit our widget builder

Stock Market News

Glaxo submits new drug application for asthma treatment

Get a free widget for your website with our latest headlines.

Top Shares pages

More share features

POPULAR Share Prices